Literature DB >> 25451866

Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.

Jerry A Katzmann1, Maria A V Willrich2, Mindy C Kohlhagen2, Robert A Kyle3, David L Murray2, Melissa R Snyder2, S Vincent Rajkumar3, Angela Dispenzieri3.   

Abstract

BACKGROUND: The use of electrophoresis to monitor monoclonal immunoglobulins migrating in the β fraction may be difficult because of their comigration with transferrin and complement proteins.
METHODS: Immunoassays specific for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ heavy/light chain (HLC) were validated for use in the clinical laboratory. We assessed sample stability, inter- and intraassay variability, linearity, accuracy, and reference intervals for all 6 assays. We tested accuracy by verifying that the sum of the concentrations for the HLC-pairs accounted for the total immunoglobulins in each of 129 healthy sera, and that the HLC-pair ratios (rHLCs) were outside the reference interval in 97% of 518 diagnostic multiple myeloma (MM) samples.
RESULTS: We assessed diagnostic samples and posttreatment sera in 32 IgG and 30 IgA patients for HLC concentrations, rHLC, and total immunoglobulins and compared these nephelometry results with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). In sample sets from patients with IgG MM, the sensitivity of SPEP was almost the same as for rHLC, and no additional advantage was conferred by running HLC assays. In pre- and posttreatment samples from patients with IgA MM, the SPEP, rHLC, and IFE identified clonality in 28%, 56%, and 61%, respectively. In addition, when M-spikes were quantifiable, the concentration of the involved HLC was linearly related to that of the SPEP M-spike, with a slope near 1.
CONCLUSIONS: The use of IgA HLC assays for monitoring β-migrating IgA monoclonal proteins can substitute for the combination of SPEP, IFE, and total IgA quantification.
© 2014 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25451866     DOI: 10.1373/clinchem.2014.231985

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Pseudo-monoclonal gammopathy: a report of four cases.

Authors:  Majd D Jawad; Ronald S Go; Thomas E Witzig; Joseph R Mikhael; Aishwarya Ravindran; David L Murrray
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

2.  Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.

Authors:  Megan M Dupuis; Barry Paul; Gavin Loitsch; Parker Mathews; Daniel Feinberg; Ian Barak; Zhiguo Li; Sascha A Tuchman; Yubin Kang
Journal:  JCO Oncol Pract       Date:  2020-04-02

3.  A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma.

Authors:  Zhipan Zheng; Kai Lin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2016-11-24

5.  Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.

Authors:  Yasuhito Suehara; Hiroyuki Takamatsu; Kota Fukumoto; Manabu Fujisawa; Kentaro Narita; Yoshiaki Usui; Masami Takeuchi; Kelly Endean; Kosei Matsue
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

6.  Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Authors:  Lucia Lopez-Anglada; Cecilia Cueto-Felgueroso; Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Ana Lopez de la Guia; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Jose Mariano Hernandez; Miquel Granell; Francisco Javier Peñalver; Ramon Garcia-Sanz; Juan Besalduch; Yolanda Gonzalez; Rafael Benigno Martinez; Miguel Teodoro Hernandez; Norma C Gutierrez; Paloma Puerta; Antonio Valeri; Bruno Paiva; Joan Blade; Maria-Victoria Mateos; Jesus San Miguel; Juan Jose Lahuerta; Joaquin Martinez-Lopez
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

7.  Putrescence to Quintessence: An Atypical Presentation of Multiple Osteoporotic Spinal Fractures Masquerading as Multiple Myeloma.

Authors:  Vivek A Ojha; Vibhu Bahl; Shobha C Ramachandra; Akila Prashant
Journal:  Cureus       Date:  2021-12-29

8.  Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.

Authors:  Maria Kraj; Barbara Kruk; Kelly Endean; Krzysztof Warzocha; Katarzyna Budziszewska; Monika Dąbrowska
Journal:  Case Rep Hematol       Date:  2015-12-31

9.  Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.

Authors:  Alfredo Gagliardi; Claudio Carbone; Angela Russo; Rosanna Cuccurullo; Anna Lucania; Paola Della Cioppa; Gabriella Misso; Michele Caraglia; Catello Tommasino; Lucia Mastrullo
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

10.  [The value of serum heavy/light chain immunoassay to assess therapeutic response in patients with multiple myeloma].

Authors:  X C Yu; W Su; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.